Study of psoriasis and related co-morbid conditions
DOI:
https://doi.org/10.18203/issn.2455-4529.IntJResDermatol20220366Keywords:
Psoriasis, Co-morbidities, Metabolic syndromeAbstract
Background: Psoriasis is a chronic, inflammatory papulosquamous disorder of the skin in which both genetic and environmental factors have a crucial role. Comorbidities tend to arise in complex disorders; they are usually multifactorial and most frequently demonstrate an inflammatory pathology. Aim and objectives of the study include: to determine the occurrence of comorbidities; to determine if the presence of these comorbidities is related to the severity of psoriasis; and to determine if the presence of comorbidities is related to the duration of psoriasis.
Methods: 100 patients diagnosed with psoriasis, attending DVL OPD of a tertiary care teaching hospital were enrolled based on inclusion and exclusion criteria. General, systemic examination and relevant investigations are done to determine co-morbidities in these patients.
Results: Among 100 patients, 70 (70%) patients were having comorbidities. Most of the patients had one comorbidity (38%) followed by two comorbidities (16%) and more than two comorbidities (15%). Dyslipidemia (56%) was the commonest comorbidity followed by diabetes mellitus (23%), obesity (20%), hypertension (18%) and metabolic syndrome (15%). 76% of patients with severe disease and 68% of patients were having mild to moderate psoriasis had co-morbidities. Among 80 patients with less than 5 years of disease duration, only 54 (67.5%) patients were having comorbidities. While 20 patients with more than 5 years of duration of disease, 16 (80%) were having comorbidities.
Conclusions: Wide range of co-morbid conditions are associated with psoriasis. The need for comprehensive screening and treatment must be recognized and addressed.
References
Nadi L. Epidemiology of Psoriasis. Curr Drug Targets Inflamm Allergy. 2004;3:121.
Ambady BM, Gopinath T, Nair BKH. Psoriasis. Indian J Dermatol Venereol Leprol. 1961;23:27-34.
Augustin M, Glaeske G, Radtke MA, Christophers E, Reich K, Schäfer I. Epidemiology and comorbidity of psoriasis in children. Br J Dermatol. 2010;162(3):633-6.
Christophers E. Comorbidities in psoriasis. Clin Dermatol. 2007;25(6):529-34.
Habif TP. Psoriasis and other papulosquamous diseases - Textbook of clinical dermatology. 5th edition. Elsevier. 2015..
Gulliver WP. Importance of screening for comorbidities in psoriasis patients. Expert Rev Dermatol. 2008;3(2),133-5.
Gerdes S, Mrowietz U. Impact of comorbidities on the management of psoriasis. Curr Probl Dermatol. 2009;38:21-36.
Gerdes S, Zahl VA, Knopf H, Weichenthal M, Mroweitz U. Comedication Related to Comorbidities: A Study in 1,203 Hospitalized Patients With Severe Psoriasis. Br J Dermatol. 2008;159(5):1116-23.
Kaye JA, Li L, Jick SS. Incidence of Risk Factors for Myocardial Infarction and Other Vascular Diseases in Patients With Psoriasis. Br J Dermatol. 2008;159(4):895-902.
Cohen AD, Sherf M, Vidavsky L, Vardy DA, Shapiro J, Meyerovitch J. Association between psoriasis and the metabolic syndrome. A cross-sectional study. Dermatology. 2008;216(2):152-5.
Pearce DJ, Morrison AE, Higgins KB, Crane MM, Balkrishnan R, Fleischer AB Jr, Feldman SR. The comorbid state of psoriasis patients in a university dermatology practice. J Dermatolog Treat. 2005;16(5-6):319-23.
Gisondi P, Tessari G, Conti A, Piaserico S, Schianchi S, Peserico A, Giannetti A, Girolomoni G. Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case-control study. Br J Dermatol. 2007;157(1):68-73.
Brauchli YB, Jick SS, Meier CR. Psoriasis and the Risk of Diabetes: A Population-based Study. Br J Dermatol. 2008;159(6):1331-7.
Azfar RS, Gelfand JM. Psoriasis and metabolic disease: epidemiology and pathophysiology. Curr Opin Rheumatol. 2008;20(4);416-22.
Lea WA, Cornish HH, Block WD. Studies on Serum Lipids, Proteins, and Lipoproteins in Psoriasis. J Invest Dermatol. 1958;30:181-5.
Shapiro J, Cohen AD, David M, Hodak E, Chodik G, Viner A, Kremer E, Heymann A. The association between psoriasis, diabetes mellitus, and atherosclerosis in Israel: a case-control study. J Am Acad Dermatol. 2007;56(4):629-34.
Armstrong AW, Lin SW, Chambers CJ, Sokolov ME, Chin DL. Psoriasis and hypertension severity: results from a case-control study. PloS One. 2011;6:e18227.
Thomas J, Ashok KN, Manoharan D, Cynthia S, Selva Prabu SK, Ahmed A. Comorbid conditions associated with Psoriasis. J Indian Soc Teledermatol. 2010;4(1).
Neimann AL, Shin DB, Wang X. Prevalence of cardiovascular risk factors in psoriasis patients. J Amer Acad Dermatol. 2006;55:829-35.
Thomas J, Ashok KN, Manoharan D, Cynthia S, Selva Prabu SK, Ahmed A. Comorbid conditions associated with Psoriasis. J Indian Soc Teledermatol. 2010;4:1.
Bonifati C, Carducci M, Fei PC, Trento E, Sacerdoti G, Fazio M. Correlated increases of tumour necrosis factor-????, interleukin-6 and granulocyte monocyte-colony stimulating factor levels in suction blister fluids and sera of psoriatic patients’ relationships with disease severity. Clin Exp Dermatol. 1994;19:383-7.
